Merrill has QLT at neutral

QLT Inc. was rated at neutral by Merrill Lynch analyst Hari Sambasivam on light Visudyne sales of $95.3 million, compared with Merrill's estimate of $101 million. The decrease was attributed in part to and increased trialing of Avastin (off-label) and destocking ahead of the launch of Lucentis. The analyst is forecasting Visudyne sales in 2006, 2007 and 2008 of $389 million, $250 million and $150 million, respectively. Estimates for the quarter include total revenues of $46.3 million and pro forma net income of $12 million, or $0.12 per share. Shares of the Vancouver, B.C.-based pharmaceutical company were down 31 cents, or 4.47%, at $6.62 on volume of 991,682 shares versus the three-month running average of 784,136 shares. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.